Insiders who reported open-market trades in the last 12 months at the companies Jason Lettmann files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Corey S. Goodman - $5.00M in ALXO purchases and sales in the last 12 months
Shelly Pinto - $12K in ALXO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Jason Lettmann is a corporate insider, tracked as CHIEF EXECUTIVE OFFICER, Director of ALX ONCOLOGY HOLDINGS INC (ALXO). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Jason Lettmann submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Jason Lettmann been buying or selling stock?
Recorded transactions: 2 open-market purchases ($99K) and 3 open-market sales ($33K) across all tracked filings.
Jason Lettmann is CHIEF EXECUTIVE OFFICER, Director of ALX ONCOLOGY HOLDINGS INC (ALXO). 8 SEC Form 4 filings on record going back to 2024, most recently on 18 August 2026. Most recent open-market trade: sold $4K of ALXO on 18 August 2026. Lifetime open-market purchases: $99K. Lifetime open-market sales: $33K.
Recent transactions
6
The latest 6 SEC Form 4 transactions reported by Jason Lettmann.
InsiderAlpha's records for Jason Lettmann go back to 2024: 8 primary Form 4 filings, an average of 2.7 per year. The typical open-market purchase is $50K (2 buys totaling $99K). The largest single buy on record is $77K of ALXO in 2025. Sales side: 3 recorded sales totaling $33K, so the filing history runs buy-heavy by dollar value. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
